Centrally administered apelin-13 induces depression-like behavior in mice

Brain Res Bull. 2012 Sep 1;88(6):574-80. doi: 10.1016/j.brainresbull.2012.06.003. Epub 2012 Jun 21.

Abstract

Apelin, a novel bioactive peptide highly concentrated in the brain, is identified as the endogenous ligand for angiotensin-like 1 receptor (APJ). The present study was designed to investigate the effect of apelin-13 on emotion-related behavior using the forced swimming test (FST) and tail suspension test (TST). Intracerebroventricular (i.c.v.) administration of apelin-13 (0.3, 1 and 3μg/mouse) dose-dependently increased the immobility time in the FST and TST, compared with control group. However, the APJ receptor antagonist apelin-13(F13A) (0.3-10μg/mouse, i.c.v.) had no influence on immobility time in the FST. The increase of immobility time induced by apelin-13 was significantly blocked by apelin-13(F13A), non-selective opioid receptor antagonist naloxone and κ-opioid receptor antagonist nor-binaltorphimine dihydrochloride (nor-BNI), respectively, but not the non-selective corticotrophin-releasing factor (CRF) receptor antagonist α-helical CRF(9-41) in the FST. In order to eliminate the possibility of a false-positive result in the FST or TST, spontaneous activity and motor function were checked. The results demonstrate that apelin-13 alone or antagonists co-administered with apelin-13 did influence spontaneous activity counts. And apelin-13 had no effect on the motor behavior in the rotarod test and wire hanging test. These results indicate that centrally administered apelin-13 elicited depression-like behavior in mice, which was mediated via APJ receptor and κ-opioid receptor, but not CRF receptor.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Apelin Receptors
  • Corticotropin-Releasing Hormone / pharmacology
  • Depression / chemically induced*
  • Injections
  • Injections, Intraventricular
  • Intercellular Signaling Peptides and Proteins / administration & dosage
  • Intercellular Signaling Peptides and Proteins / chemistry
  • Intercellular Signaling Peptides and Proteins / pharmacology*
  • Male
  • Mice
  • Motor Activity / drug effects
  • Naloxone / pharmacology
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Peptide Fragments / pharmacology
  • Receptor, Angiotensin, Type 1 / agonists*
  • Receptor, Angiotensin, Type 1 / physiology
  • Receptors, Corticotropin-Releasing Hormone / antagonists & inhibitors
  • Receptors, G-Protein-Coupled / agonists*
  • Receptors, G-Protein-Coupled / physiology
  • Receptors, Opioid, kappa / antagonists & inhibitors
  • Receptors, Opioid, kappa / physiology*
  • Rotarod Performance Test
  • Single-Blind Method

Substances

  • Apelin Receptors
  • Aplnr protein, mouse
  • Intercellular Signaling Peptides and Proteins
  • Peptide Fragments
  • Receptor, Angiotensin, Type 1
  • Receptors, Corticotropin-Releasing Hormone
  • Receptors, G-Protein-Coupled
  • Receptors, Opioid, kappa
  • apelin-13 peptide
  • apelin-13, Ala(13)-
  • Naloxone
  • norbinaltorphimine
  • Naltrexone
  • Corticotropin-Releasing Hormone
  • corticotropin releasing hormone (9-41)